Market Overview

Teva Holders Shrug at FDA Approval of Generic-Version of Novartis' TOBI in US

Share:
Related TEVA
Deutsche Bank Offers Quick Thoughts On Teva Pharmaceutical's Generic Nexium
Benzinga's Weekend M&A Chatter
Biotech Stocks Down Despite Strong Amgen Quarter (Investor's Business Daily)
Related NVS
Morning Market Gainers
Benzinga's Top #PreMarket Gainers
Novartis (NVS) Up on Earnings and Revenue Beat in Q4 - Analyst Blog (Zacks)

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announces today that the U.S. Food and Drug Administration has granted approval of the generic equivalent to TOBI^® (Tobramycin Inhalation Solution USP) in the United States. Pursuant to an agreement with Novartis (NYSE: NVS) on this product, Teva expects to launch this product in late November. Marketed by Novartis, TOBI^® had annual sales of approximately $350 million in the United States, according to IMS data as of June 30, 2013.

Posted-In: News FDA

 

Related Articles (TEVA + NVS)

Around the Web, We're Loving...

Get Benzinga's Newsletters